631 related articles for article (PubMed ID: 10408861)
21. Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid.
Turpeinen AK; Takala TO; Nuutila P; Axelin T; Luotolahti M; Haaparanta M; Bergman J; Hämäläinen H; Iida H; Mäki M; Uusitupa MI; Knuuti J
Diabetes; 1999 Jun; 48(6):1245-50. PubMed ID: 10342811
[TBL] [Abstract][Full Text] [Related]
22. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
Minn H; Zasadny KR; Quint LE; Wahl RL
Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
[TBL] [Abstract][Full Text] [Related]
23. Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate.
Visser FC
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S12-8. PubMed ID: 11286301
[TBL] [Abstract][Full Text] [Related]
24. Effect of hyperinsulinemia on myocardial fluorine-18-FDG uptake.
Ng CK; Soufer R; McNulty PH
J Nucl Med; 1998 Mar; 39(3):379-83. PubMed ID: 9529278
[TBL] [Abstract][Full Text] [Related]
25. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.
Vitale GD; deKemp RA; Ruddy TD; Williams K; Beanlands RS
J Nucl Med; 2001 Dec; 42(12):1730-6. PubMed ID: 11752067
[TBL] [Abstract][Full Text] [Related]
26. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels.
Monti LD; Lucignani G; Landoni C; Moresco RM; Piatti P; Stefani I; Pozza G; Fazio F
Diabetes; 1995 May; 44(5):537-42. PubMed ID: 7729612
[TBL] [Abstract][Full Text] [Related]
27. Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Schinkel AF; Bax JJ; Valkema R; Elhendy A; van Domburg RT; Vourvouri EC; Bountioukos MA; Krenning EP; Roelandt JR; Poldermans D
J Nucl Med; 2003 Jun; 44(6):877-83. PubMed ID: 12791813
[TBL] [Abstract][Full Text] [Related]
28. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Ahrén B
Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
[TBL] [Abstract][Full Text] [Related]
29. [18F-FDG uptake of lymphoma lesions of various histological subtypes].
Ma LF; Fan W
Ai Zheng; 2009 Apr; 28(4):425-30. PubMed ID: 19622306
[TBL] [Abstract][Full Text] [Related]
30. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
[TBL] [Abstract][Full Text] [Related]
31. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans.
Choi Y; Brunken RC; Hawkins RA; Huang SC; Buxton DB; Hoh CK; Phelps ME; Schelbert HR
Eur J Nucl Med; 1993 Apr; 20(4):308-18. PubMed ID: 8491223
[TBL] [Abstract][Full Text] [Related]
32. Dose-response effects of free fatty acids on glucose and lipid metabolism during somatostatin blockade of growth hormone and insulin in humans.
Gormsen LC; Jessen N; Gjedsted J; Gjedde S; Nørrelund H; Lund S; Christiansen JS; Nielsen S; Schmitz O; Møller N
J Clin Endocrinol Metab; 2007 May; 92(5):1834-42. PubMed ID: 17341555
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis.
Lucidi P; Rossetti P; Porcellati F; Pampanelli S; Candeloro P; Andreoli AM; Perriello G; Bolli GB; Fanelli CG
Diabetes; 2010 Jun; 59(6):1349-57. PubMed ID: 20299466
[TBL] [Abstract][Full Text] [Related]
34. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
36. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans.
Rigazio S; Lehto HR; Tuunanen H; Någren K; Kankaanpaa M; Simi C; Borra R; Naum AG; Parkkola R; Knuuti J; Nuutila P; Iozzo P
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E413-9. PubMed ID: 18505832
[TBL] [Abstract][Full Text] [Related]
37. Antilipolytic drug boosts glucose metabolism in prostate cancer.
Andersen KF; Divilov V; Koziorowski J; Pillarsetty N; Lewis JS
Nucl Med Biol; 2013 May; 40(4):524-8. PubMed ID: 23454248
[TBL] [Abstract][Full Text] [Related]
38. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
[TBL] [Abstract][Full Text] [Related]
39. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Blachère JC; Pérusse F; Bukowiecki LJ
Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
[TBL] [Abstract][Full Text] [Related]
40. Myocardial glucose metabolism in patients with hypertrophic cardiomyopathy: assessment by F-18-FDG PET study.
Uehara T; Ishida Y; Hayashida K; Shimonagata T; Miyake Y; Sago M; Oka H; Nagata S; Miyatake K; Nishimura T
Ann Nucl Med; 1998 Apr; 12(2):95-103. PubMed ID: 9637280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
